While there was no significant difference between anti‐ELTD1, OKN or combined therapies, combined therapy (11%) seems to have a more significant downward trend when looking at the average Ki‐67 positivity within the tumour region when compared against anti‐ELTD1 (24%) and OKN (22%) treated. The gene discussed is MKI67; the disease is neoplasm.